Table 4.
Logistic Regression Analysis of Factors Associated with Disease Severity in HCT and CAR-T Cell Therapy Recipients Diagnosed with COVID-19
| Characteristic | COVID-19 Severity (Mild vs Moderate-Severe) | |
|---|---|---|
| OR (95% CI) | P Value | |
| Type of cell therapy (allo-HCT vs auto-HCT/CAR-T) | 3.64 (1.23-10.78) | .020 |
| Current IST | 5.91 (1.76-19.81) | .004 |
| Prior grade II-IV acute GVHD | 4.56 (1.10-18.86) | .036 |
Not significant: age (P = .849), sex (P = .414), hematologic malignancy (P = .169), active GVHD (P = .094), concurrent infections (P = .518), lymphopenia (P = .055), ferritin (P = .147), neutrophil:lymphocyte ratio (P = .168), platelet:lymphocyte ratio (P = .159).
Abbreviations: COVID-19, coronavirus disease 2019; HCT, hematopoietic stem cell transplant; CAR-T, chimeric antigen receptor-T cell therapy.